The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution.

Abstract:

BACKGROUND:While there is growing demand for information about comparative effectiveness (CE), there is substantial debate about whether and when observational studies have sufficient quality to support decision making. OBJECTIVE:To develop and test an item checklist that can be used to qualify those observational CE studies sufficiently rigorous in design and execution to contribute meaningfully to the evidence base for decision support. METHODS:An 11-item checklist about data and methods (the GRACE checklist) was developed through literature review and consultation with experts from professional societies, payer groups, the private sector, and academia. Since no single gold standard exists for validation, checklist item responses were compared with 3 different types of external quality ratings (N=88 articles). The articles compared treatment effectiveness and/or safety of drugs, medical devices, and medical procedures. We validated checklist item responses 3 ways against external quality ratings, using published articles of observational CE or safety studies: (a) Systematic Review-quality assessment from a published systematic review; (b) Single Expert Review-quality assessment made according to the solicited "expert opinion" of a senior researcher; and (c) Concordant Expert Review-quality assessments from 2 experts for which there was concordance. Volunteers (N=113) from 5 continents completed 280 article assessments using the checklist. Positive and negative predictive values (PPV, NPV, respectively) of individual items were estimated to compare testers' assessments with those of experts. RESULTS:Taken as a whole, the scale had better NPV than PPV, for both data and methods. The most consistent predictor of quality relates to the validity of the primary outcomes measurement for the study purpose. Other consistent markers of quality relate to using concurrent comparators, minimizing the effects of bias by prudent choice of covariates, and using sensitivity analysis to test robustness of results. Concordance of expert opinion on the quality of the rated articles was 52%; most checklist items performed better. CONCLUSIONS:The 11-item GRACE checklist provides guidance to help determine which observational studies of CE have used strong scientific methods and good data that are fit for purpose and merit consideration for decision making. The checklist contains a parsimonious set of elements that can be objectively assessed in published studies, and user testing shows that it can be successfully applied to studies of drugs, medical devices, and clinical and surgical interventions. Although no scoring is provided, study reports that rate relatively well across checklist items merit in-depth examination to understand applicability, effect size, and likelihood of residual bias. The current testing and validation efforts did not achieve clear discrimination between studies fit for purpose and those not, but we have identified a critical, though remediable, limitation in our approach. Not specifying a specific granular decision for evaluation, or not identifying a single study objective in reports that included more than one, left reviewers with too broad an assessment challenge. We believe that future efforts will be more successful if reviewers are asked to focus on a specific objective or question. Despite the challenges encountered in this testing, an agreed upon set of assessment elements, checklists, or score cards is critical for the maturation of this field. Substantial resources will be expended on studies of real-world effectiveness, and if the rigor of these observational assessments cannot be assessed, then the impact of the studies will be suboptimal. Similarly, agreement on key elements of quality will ensure that budgets are appropriately directed toward those elements. Given the importance of this task and the lessons learned from these extensive efforts at validation and user testing, we are optimistic about the potential for improved assessments that can be used for diverse situations by people with a wide range of experience and training. Future testing would benefit by directing reviewers to address a single, granular research question, which would avoid problems that arose by using the checklist to evaluate multiple objectives, by using other types of validation test sets, and by employing further multivariate analysis to see if any combination or sequence of item responses has particularly high predictive validity.

authors

Dreyer NA,Velentgas P,Westrich K,Dubois R

doi

10.18553/jmcp.2014.20.3.301

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

301-8

issue

3

eissn

2376-0540

issn

2376-1032

pii

2014(20)3: 301-308

journal_volume

20

pub_type

杂志文章
  • Meeting Abstracts - Annual Meeting 2016.

    abstract::The AMCP Abstracts program provides a forum through which authors can share their insights and outcomes of advanced managed care practice through publication in AMCP's Journal of Managed Care & Specialty Pharmacy (JMCP). Most of the reviewed and unreviewed abstracts are presented as posters so that interested AMCP mee...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.4.S1

    authors:

    更新日期:2016-04-01 00:00:00

  • Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.

    abstract::We write to comment on a recently published study by Delea et al. in the January 2015 issue of JMCP that evaluated the cost-effectiveness (CE) of sunitinib (SU) versus pazopanib (PAZ) as first-line treatment for metastatic renal cell carcinoma (mRCC) from a U.S. third-party payer perspective.1 This analysis was based ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 评论,信件

    doi:10.18553/jmcp.2015.21.9.834

    authors: Benedict A,Ramaswamy K,Sandin R

    更新日期:2015-09-01 00:00:00

  • Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.

    abstract:BACKGROUND:Adherence to biologic disease-modifying antirheumatic drugs (bDMARDs) among patients with rheumatoid arthritis (RA) is often suboptimal in routine clinical practice. Low or nonadherence can reduce the effectiveness of bDMARD therapies. OBJECTIVE:To evaluate filling of newly prescribed initial bDMARDs for th...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.3.209

    authors: Harnett J,Wiederkehr D,Gerber R,Gruben D,Bourret J,Koenig A

    更新日期:2016-03-01 00:00:00

  • Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.

    abstract:BACKGROUND:Treatment patterns for metastatic colorectal cancer (mCRC) patients have changed considerably over the last decade with the introduction of new chemotherapies and targeted biologics. These treatments are often administered in various sequences with limited evidence regarding their cost-effectiveness. OBJECT...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.1.64

    authors: Parikh RC,Du XL,Robert MO,Lairson DR

    更新日期:2017-01-01 00:00:00

  • Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.

    abstract:BACKGROUND:Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, following the publication o...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.12.1214

    authors: Ahuja V,Sohn MW,Birge JR,Syverson C,Budiman-Mak E,Emanuele N,Cooper JM,Huang ES

    更新日期:2015-12-01 00:00:00

  • The Economic Burden of Opioid Abuse: Updated Findings.

    abstract:BACKGROUND:Opioid pain relievers can be highly effective in providing relief for patients suffering from pain. At the same time, prescription opioid abuse, dependence, overdose, and poisoning (hereinafter "abuse") have become a national public health concern. Opioid abuse is also costly: previous estimates of the annua...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.16265

    authors: Kirson NY,Scarpati LM,Enloe CJ,Dincer AP,Birnbaum HG,Mayne TJ

    更新日期:2017-04-01 00:00:00

  • Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.

    abstract:BACKGROUND:Diabetes mellitus is associated with substantial morbidity and mortality. With the rise in prevalence of diabetes, there has been an increased need for clinical pharmacy services focused on diabetes management in ambulatory clinics. However, more data IS needed to determine the overall impact that clinical p...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.9.914

    authors: Chung N,Rascati K,Lopez D,Jokerst J,Garza A

    更新日期:2014-09-01 00:00:00

  • Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.

    abstract:BACKGROUND:The implementation of Medicare Part D provided insurance coverage for outpatient medications, but when persons reach the "gap," they have very limited or no medication insurance coverage until they reach a second threshold for catastrophic coverage. In addition, some patients have a low-income subsidy (LIS),...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.8.862

    authors: Park H,Rascati KL,Lawson KA,Barner JC,Richards KM,Malone DC

    更新日期:2014-08-01 00:00:00

  • Current Procedural Terminology Codes for Medication Therapy Management in Administrative Data.

    abstract:BACKGROUND:Three pharmacist-specific Current Procedural Terminology (CPT) codes exist to facilitate medication therapy management (MTM) reimbursement (codes 99605, 99606, and 99607). However, no studies have used CPT codes in administrative claims databases to identify subjects who have received MTM services. OBJECTIV...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.10.1297

    authors: Axon DR,Chinthammit C,Tate J,Taylor AM,Leal S,Pickering M,Black H,Warholak T,Campbell PJ

    更新日期:2020-10-01 00:00:00

  • A case study in generic drug use: should there be risk adjustment in incentive payments for the use of generic medications?

    abstract:BACKGROUND:Encouraging generic drug use has reduced health care costs for payers and consumers, but the availability of therapeutically interchangeable medications or generic medications of choice is not equal across disease states. The extent to which systems of care are able to substitute with generics is not well un...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.11.1093

    authors: Walton SM,Rash C,Lambert BL,Galanter WL

    更新日期:2014-11-01 00:00:00

  • Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

    abstract:BACKGROUND:New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens. OBJECTIVE:To evaluate the cost-effectiveness of trea...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.1.29

    authors: Carlson JJ,Guzauskas GF,Chapman RH,Synnott PG,Liu S,Russo ET,Pearson SD,Brouwer ED,Ollendorf DA

    更新日期:2018-01-01 00:00:00

  • Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up.

    abstract:BACKGROUND:In recent years, comparative effectiveness tools and methods have evolved to assist health care decision makers in identifying optimal therapies. In-person training programs on comparative effectiveness research may be helpful in understanding and applying this information. OBJECTIVE:To provide a follow-up ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.6.618

    authors: Augustine J,Warholak TL,Hines LE,Sun D,Brown M,Hurwitz J,Taylor AM,Brixner D,Cobaugh DJ,Schlaifer M,Malone DC

    更新日期:2016-06-01 00:00:00

  • A Retrospective, Longitudinal, Claims-Based Comparison of Concomitant Diagnoses Between Individuals with and Without Down Syndrome.

    abstract:BACKGROUND:Individuals with Down syndrome (DS) experience various comorbidities in excess of the prevalence seen among the non-DS population. However, the extent of the excess burden of comorbidities specifically within commercially and publicly insured DS populations aged < 21 years is not currently known. OBJECTIVES...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.7.761

    authors: Kong AM,Hurley D,Evans KA,Brixner D,Csoboth C,Visootsak J

    更新日期:2017-07-01 00:00:00

  • Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.

    abstract:BACKGROUND:Prescription opioid abuse is associated with substantial economic burden, with estimates of incremental annual per-patient health care costs of diagnosed opioid abuse exceeding $10,000 in prior literature. A subset of patients diagnosed with opioid abuse has disproportionately high health care costs, but lit...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.10.902

    authors: Shei A,Rice JB,Kirson NY,Bodnar K,Enloe CJ,Birnbaum HG,Holly P,Ben-Joseph R

    更新日期:2015-10-01 00:00:00

  • Understanding and overcoming barriers to medication adherence: a review of research priorities.

    abstract::Improving medication adherence has been identified as a crucial step towards improving health outcomes for patients with chronic disease and has provided the motivation for many changes in our health care system. Despite the volume of research done on this topic, however, we still lack important basic information abou...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,评审

    doi:10.18553/jmcp.2014.20.8.775

    authors: Seabury SA,Gupta CN,Philipson TJ,Henkhaus LE,PhRMA Medication Adherence Advisory Council.

    更新日期:2014-08-01 00:00:00

  • Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.

    abstract:BACKGROUND:Acromegaly is a chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels most often caused by a pituitary adenoma. Clinical presentation of the disease includes coarsening of the facial features, soft-tissue swelling of the hands and feet, and overgro...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.12.1106

    authors: Placzek H,Xu Y,Mu Y,Begelman SM,Fisher M

    更新日期:2015-12-01 00:00:00

  • Change in Proportion of Days Covered for Statins Following Implementation of a Pharmacy Student Adherence Outreach Program.

    abstract:BACKGROUND:Nearly half of statin users discontinue therapy within the first year of treatment. Nonadherence to statin therapy may lead to an increased risk of atherosclerotic cardiovascular disease and, thus, higher costs due to hospitalizations. Value-based care models, such as accountable care organizations (ACO), ar...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.5.588

    authors: Tamargo C,Sando K,Prados Y,Cowart K

    更新日期:2019-05-01 00:00:00

  • Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease.

    abstract:BACKGROUND:Rosacea is a chronic skin disorder that presents with abnormal vascular and inflammatory conditions. Clinical manifestations include flushing, facial erythema, inflammatory papules and pustules, telangiectasias, edema, and watery or irritated eyes. OBJECTIVE:To discuss the evolving pathophysiology of rosace...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,评审

    doi:10.18553/jmcp.2014.20.6.623

    authors: Feldman SR,Huang WW,Huynh TT

    更新日期:2014-06-01 00:00:00

  • Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.

    abstract:BACKGROUND:The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Dr...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.1.27

    authors: Abbass IM,Caplan EO,Ng DB,Kristy R,Schermer CR,Bradt P,Collins JM,Chan WM,Suehs BT

    更新日期:2017-01-01 00:00:00

  • Adherence to Disease-Modifying Therapies for Multiple Sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is a neurological degenerative chronic condition without cure. However, long-term disease-modifying therapies (DMTs) help reduce the severity of MS symptoms. Adherence to DMTs is key to their success. Several studies have analyzed what makes patients adherent to their DMTs. As new DMT...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.12.1394

    authors: Higuera L,Carlin CS,Anderson S

    更新日期:2016-12-01 00:00:00

  • Prevalence, Patterns, and Cost of Care for Children with Cerebral Palsy Enrolled in Medicaid Managed Care.

    abstract:BACKGROUND:In the United States, many children with cerebral palsy (CP) obtain health care coverage through managed Medicaid, but little is known about the current demographics or management of this high-need, complex population. OBJECTIVE:To develop U.S. population-level information about the prevalence of CP, manage...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.7.817

    authors: Pulgar S,Bains S,Gooch J,Chambers H,Noritz GH,Wright E,Sawhney TG,Pyenson B,Ferro C

    更新日期:2019-07-01 00:00:00

  • Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.

    abstract:BACKGROUND:Psoriasis is a chronic, hyper-proliferative dermatological condition associated with joint symptoms known as psoriatic arthritis (PsA). In a 2013 review, the total economic burden of PsA was estimated at $51.7-$63.2 billion. The economic burden of moderate to severe psoriasis patients has reduced significant...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.7.654

    authors: Lee S,Xie L,Wang Y,Vaidya N,Baser O

    更新日期:2018-07-01 00:00:00

  • Impact of a Combined Value-Based Insurance Design and Medication Therapy Management Program on Diabetes Medication Adherence.

    abstract:BACKGROUND:Value-based insurance design (VBID) waives or reduces prescription copayments in order to decrease member cost barriers to refilling medications. Medication therapy management (MTM) is a member clinical intervention designed to reinforce members' knowledge of their medications, which addresses barriers to me...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.11.1303

    authors: Peaslee A,Wickizer M,Olson J,Topp R

    更新日期:2016-11-01 00:00:00

  • Evaluating Patient Preferences for Different Incentive Programs to Optimize Pharmacist-Provided Patient Care Program Enrollment.

    abstract:BACKGROUND:Employers have increased efforts to engage employees in health and wellness programs. Providing employees with incentives to participate in these programs has been shown to improve overall enrollment and engagement. One program that has had challenges with enrollment and engagement is medication therapy mana...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.11.1140

    authors: Tomaszewski D,Cernohous T,Vaidyanathan R

    更新日期:2017-11-01 00:00:00

  • Grim Provider and Supplier Gross Margins of 1.8%-3.7% if CMS-1670-P Is Finalized As Proposed.

    abstract:DISCLOSURES:The author provides consulting services to the pharmaceutical industry, including manufacturers, health plans, employers, and specialty pharmacies, and is a member of the editorial advisory board of Specialty Pharmacy News. The author reports no financial or other conflicts of interest related to the subjec...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.16091

    authors: Rubinstein E

    更新日期:2016-08-01 00:00:00

  • Seeing the Forest Through the Trees: Improving Adherence Alone Will Not Optimize Medication Use.

    abstract:UNLABELLED:Medication adherence is a problem that has received widespread attention in the medical literature and health policy circles. With the increased emphasis on recognizing and rewarding quality in the U.S. health care system, medication adherence measures are increasingly being adopted to assess quality of medi...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.5.598

    authors: Sorensen TD,Pestka DL,Brummel AR,Rehrauer DJ,Ekstrand MJ

    更新日期:2016-05-01 00:00:00

  • The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis.

    abstract:DISCLOSURES:No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amge...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 评论,信件

    doi:10.18553/jmcp.2020.26.3.334

    authors: Hiligsmann M,Reginster JY,Silverman S

    更新日期:2020-03-01 00:00:00

  • Understanding reasons for nonadherence to medications in a medicare part d beneficiary sample.

    abstract:BACKGROUND:Poor medication adherence is a predictor of poor health outcomes, especially in populations with chronic diseases. Although several self-reported measures of medication adherence exist, the scope of each is limited.  OBJECTIVE:To identify barriers to medication adherence in order to facilitate effective del...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.5.391

    authors: Hincapie AL,Taylor AM,Boesen KP,Warholak T

    更新日期:2015-05-01 00:00:00

  • Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.

    abstract:BACKGROUND:Immunoglobulin (Ig) is a costly blood product prescribed as immune replacement or modulation therapy to treat a wide spectrum of medical conditions. While the FDA has approved Ig for a limited number of indications, there are multiple off-label uses that have demonstrated proven clinical benefit or are curre...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.4.357

    authors: Tonkovic B,Rutishauser LK

    更新日期:2014-04-01 00:00:00

  • The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.

    abstract:BACKGROUND:The management of sickle cell disease (SCD), an inherited, chronic, and multifaceted condition, is associated with considerable health care resource utilization (HRU) and costs, especially for Medicaid. Anemia affects most patients with SCD and correlates with end-organ damage (EOD), such as stroke, chronic ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.20009

    authors: Campbell A,Cong Z,Agodoa I,Song X,Martinez DJ,Black D,Lew CR,Varker H,Chan C,Lanzkron S

    更新日期:2020-09-01 00:00:00